# Oncopeptides > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/oncopeptides). ## Overview Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases. The company is known for its proprietary Peptide-Drug Conjugate (PDC) platform, which has shown promise in treating multiple myeloma and is being expanded to other indications such as glioblastoma. Oncopeptides has achieved significant market access in Europe, particularly in Italy and Spain, and is actively pursuing opportunities in Japan. The company's flagship product, Pepaxti, has driven substantial sales growth, reflecting its strong demand in key markets. ## Products & services • Pepaxti (melflufen) for multiple myeloma • Peptide-Drug Conjugate (PDC) platform • Research and development in hematology • Market access and commercialization services • Strategic partnerships for drug licensing - **Pharmaceuticals** (70%) — Includes Pepaxti and other drug products - **Research and Development** (20%) — Focuses on PDC platform and new indications - **Market Access Services** (10%) — Facilitates drug approval and commercialization - Pepaxti (melflufen) for multiple myeloma - Peptide-Drug Conjugate (PDC) platform - Research and development in hematology - Market access and commercialization services - Strategic partnerships for drug licensing ## Customers Oncopeptides primarily serves healthcare providers and institutions specializing in hematology and oncology. The company's main customers include hospitals and clinics that treat patients with multiple myeloma and other hematological malignancies. In Europe, Oncopeptides has established a strong presence, particularly in Italy and Spain, where it has secured market access for Pepaxti. The company is also targeting the Japanese market through strategic partnerships with local pharmaceutical firms. Oncopeptides' customers value the innovative therapies that address high unmet medical needs, offering new treatment options for complex diseases. - **Healthcare Providers** (primary) — Purchase Pepaxti for treating multiple myeloma - **Pharmaceutical Partners** (secondary) — Engage in licensing and distribution agreements - **Research Institutions** (emerging) — Collaborate on PDC platform development - Hospitals and clinics treating multiple myeloma - Oncologists and hematologists seeking innovative therapies - Healthcare institutions in Europe, especially Italy and Spain - Japanese pharmaceutical companies for strategic partnerships - Patients with high unmet medical needs in hematology ## Geography Oncopeptides is headquartered in Stockholm, Sweden, and has a significant presence in the European market, particularly in Italy and Spain, where it has successfully launched its flagship product, Pepaxti. The company is also exploring opportunities in Japan, having engaged in advanced negotiations with a local pharmaceutical company. While Europe remains the primary market, Oncopeptides is strategically expanding its geographic footprint to include Asia. The company's operations are supported by subsidiaries in Germany and other European countries, facilitating market access and commercialization efforts. - Headquartered in Stockholm, Sweden - Strong market presence in Italy and Spain - Advanced negotiations for market entry in Japan - Subsidiaries in Germany and other European countries - Strategic expansion into Asian markets ## Strategy Oncopeptides is focused on expanding its Peptide-Drug Conjugate (PDC) platform to address new indications beyond multiple myeloma, such as glioblastoma. The company aims to achieve positive cash flow by 2027 by optimizing its operations and focusing on high-potential markets. Strategic priorities include securing market access in key regions, enhancing the product pipeline, and forming strategic partnerships in Japan. Oncopeptides is also streamlining its operations in Germany to achieve profitability at the country level by 2026. These strategic initiatives are designed to strengthen the company's competitive position and drive long-term growth. - **Expand PDC platform** (medium-term) — To address new high-value indications - **Achieve positive cash flow** (long-term) — To ensure financial sustainability - **Market access** (short-term) — To increase sales and market presence - Expand PDC platform to new indications like glioblastoma - Achieve positive cash flow by 2027 - Secure market access in key regions - Form strategic partnerships in Japan - Streamline operations in Germany for profitability ## Risks Oncopeptides faces several risks, including regulatory challenges in securing market access for its products in new regions, which can delay commercialization efforts. The company's financial performance is also sensitive to fluctuations in demand for Pepaxti, particularly in key markets like Germany. Additionally, geopolitical risks, such as changes in healthcare policies in Europe, could impact market dynamics. Oncopeptides must also manage the risks associated with its strategic expansion into Japan, where negotiations with local partners are ongoing. The company continuously evaluates these risks to mitigate their potential impact on its operations and financial performance. - **Regulatory challenges** [high] — Delays in market access - **Demand fluctuations** [medium] — Affects revenue stability - **Geopolitical risks** [high] — Impact on healthcare policies - Regulatory challenges in new markets - Fluctuations in demand for Pepaxti - Geopolitical risks affecting healthcare policies - Strategic expansion risks in Japan - Dependency on key European markets ## Accounting Oncopeptides' financial statements are influenced by the timing of revenue recognition, particularly as it secures market access for Pepaxti in new regions. The company must carefully manage its cash flow and expenses to align with its growth strategy, which includes significant investments in market expansion and R&D. Estimates and provisions for future liabilities, such as potential regulatory fines or penalties, are critical areas of judgment. The company applies IAS 34 for interim financial reporting and adheres to ESMA guidelines for alternative key figures, ensuring transparency and comparability of its financial performance. - **Revenue recognition timing** - **Cash flow management** - **Estimates and provisions** - Timing of revenue recognition affects reported sales - Cash flow management critical for growth strategy - Estimates and provisions for future liabilities - Adheres to IAS 34 for interim reporting - Uses ESMA guidelines for alternative key figures --- *Last updated: 2026-08-11T04:04:55.051089+00:00*